Skip to content
Decorative Image With Article Title "SHP2 Inhibitors: Progress And Perspectives In 2024

SHP2 Inhibitors: Progress and Perspectives in 2024

In 2024, SHP2 inhibitors (SHP2i) remain at the forefront of drug discovery, particularly in the realm of oncology.  While there are some perspectives suggesting that the emphasis on SHP2 may indicate a disproportionate preference for well-established targets, current developments underscore…

Ilaria Di Lorenzo (IRBM) And Carlo Tosti (UCBM) Sign 3 Year Framework Agreement To Advance Pharmaceutical Innovation

Advancing Pharmaceutical Innovation: IRBM, Campus Bio-Medico University of Rome (UCBM), and Campus Bio-Medico University Polyclinic Foundation (FPUCBM) Establish Framework Agreement

With a three-year duration, it will operate in the fields of oncology, biopharmaceuticals, neuroscience, musculoskeletal system, and infectious diseases. Rome, March 28, 2024 - A three-year framework collaboration agreement has been signed between the Campus Bio-Medico University of Rome (UCBM),…

IRBM Honored At The 44th Annual Edison Patent Awards

IRBM Recognized at the 44th Annual Edison Patent Awards

IRBM is proud to announce its recognition at the 44th Annual Edison Patent Awards, held on November 15th at the Liberty Science Center in Jersey City, New Jersey. The event, organized by the Research & Development Council of New Jersey,…

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

IRBM, Rainwater Charitable Foundation (RCF, based in Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) announce the start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. Financial details are not disclosed.




Back To Top